4//SEC Filing
STANKOVICH THOMAS 4
Accession 0001235802-23-000030
CIK 0001427570other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:11 PM ET
Size
9.9 KB
Accession
0001235802-23-000030
Insider Transaction Report
Form 4
STANKOVICH THOMAS
Chief Financial Officer
Transactions
- Sale
Common Stock, $0.001 par value per share
2023-01-24$7.49/sh−48$360→ 6,461 total - Sale
Common Stock, $0.001 par value per share
2023-01-24$7.49/sh−110$824→ 6,351 total - Sale
Common Stock, $0.001 par value per share
2023-02-02$13.29/sh−157$2,087→ 6,194 total - Sale
Common Stock, $0.001 par value per share
2023-02-28$4.25/sh−103$438→ 6,091 total
Footnotes (2)
- [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
- [F2]On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.
Documents
Issuer
ReShape Lifesciences Inc.
CIK 0001427570
Entity typeother
Related Parties
1- filerCIK 0001181166
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:11 PM ET
- Size
- 9.9 KB